文献速递其他结缔组织病

尼达尼布治疗系统性硬化相关间质性肺病:按自身抗体状态和改良Rodnan皮肤厚度评分的亚组分析

Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
PubMed 文献 · Arthritis Rheumatol · 2022-02-13

基于SENSCIS试验数据,评估尼达尼布与安慰剂在系统性硬化相关间质性肺病(SSc-ILD)不同亚组中的疗效。亚组依据抗拓扑异构酶I抗体(ATA)状态、改良Rodnan皮肤厚度评分(MRSS)和SSc亚型划分。结果显示尼达尼布减少用力肺活量(FVC)年下降率在各亚组间无显著异质性(交互作用P均>0.05)。

要点

  • 尼达尼布对FVC年下降率的减缓在各ATA状态、MRSS和SSc亚型亚组间无显著异质性。
  • ATA阴性患者调整后FVC下降率差异为57.2 ml/年(95%CI -3.5, 118.0),ATA阳性为29.9 ml/年(95%CI -19.1, 78.8)。
  • 基线MRSS≥18患者调整后差异为88.7 ml/年(95%CI 7.7, 169.8),MRSS<18为26.4 ml/年(95%CI -16.8, 69.6)。

核心结论

  • 在SSc-ILD患者中,尼达尼布与安慰剂相比减少FVC年下降率的效果在ATA状态、MRSS和SSc亚型亚组间无显著异质性。

研究设计与样本

  • 基于SENSCIS试验的事后亚组分析,576例接受尼达尼布或安慰剂治疗的SSc-ILD患者,按ATA状态分层随机。

主要发现

  • 尼达尼布减少FVC年下降率的调整后差异在ATA阴性患者为57.2 ml/年(95%CI -3.5, 118.0),ATA阳性患者为29.9 ml/年(95%CI -19.1, 78.8)。
  • 基线MRSS≥18患者调整后差异为88.7 ml/年(95%CI 7.7, 169.8),MRSS<18患者为26.4 ml/年(95%CI -16.8, 69.6)。
  • dcSSc患者调整后差异为56.6 ml/年(95%CI 3.2, 110.0),lcSSc患者为25.3 ml/年(95%CI -28.9, 79.6)。
  • 所有探索性交互作用P值均无统计学显著性(均P>0.05)。

关键数值与推荐

  • 基线时60.8%的患者ATA阳性,51.9%为dcSSc,77.5%的MRSS数据可及患者MRSS<18。

临床怎么用

  • 尼达尼布对SSc-ILD患者FVC年下降率的减缓作用在不同ATA状态、MRSS和SSc亚型亚组中一致,支持其用于广泛SSc-ILD人群。

局限性

  • 亚组分析为探索性,交互作用检验无统计学显著性,不能排除样本量不足导致检验效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using data from the SENSCIS trial, these analyses were undertaken to assess the effects of nintedanib versus placebo in subgroups of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), based on characteristics previously identified as being associated with the progression of SSc-ILD. METHODS: Patients with SSc-ILD were randomized to receive either nintedanib or placebo, stratified by anti-topoisomerase I antibody (ATA) status. We assessed the rate of decline in forced vital capacity (FVC) (expressed in ml/year) over 52 weeks in subgroups based on baseline ATA status, modified Rodnan skin thickness score (MRSS) (<18 versus ≥18), and SSc subtype (limited cutaneous SSc [lcSSc] versus diffuse cutaneous SSc [dcSSc]). RESULTS: At baseline, 60.8% of 576 patients who received treatment with either nintedanib or placebo were positive for ATA, 51.9% had dcSSc, and 77.5% of 574 patients with MRSS data available had an MRSS of <18. The effect of nintedanib versus placebo on reducing the rate of decline in FVC (ml/year) was numerically more pronounced in ATA-negative patients compared to ATA-positive patients (adjusted difference in the rate of FVC decline, 57.2 ml/year [95% confidence interval (95% CI) -3.5, 118.0] versus 29.9 ml/year [95% CI -19.1, 78.8]), in patients with a baseline MRSS ≥18 compared to those with a baseline MRSS of <18 (adjusted difference in the rate of FVC decline, 88.7 ml/year [95% CI 7.7, 169.8] versus 26.4 ml/year [95% CI -16.8, 69.6]), and in patients with dcSSc compared to those with lcSSc (adjusted difference in the rate of FVC decline, 56.6 ml/year [95% CI 3.2, 110.0] versus 25.3 ml/year [95% CI -28.9, 79.6]). However, all exploratory interaction P values were nonsignificant (all P > 0.05), indicating that there was no heterogeneity in the effect of nintedanib versus placebo between these subgroups of patients. CONCLUSION: In patients with SSc-ILD, reduction in the annual rate of decline in FVC among patients receiving nintedanib compared to those receiving placebo was not found to be heterogenous across subgroups based on ATA status, MRSS, or SSc subtype.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kuwana M, Allanore Y, Denton CP, et al. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis Rheumatol. 2022. PMID: 34514739. doi:10.1002/art.41965

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。